Loading clinical trials...
Loading clinical trials...
A PHASE III, OPEN, MULTI-CENTRE, CONTROLLED STUDY TO EVALUATE THE LONG-TERM ANTIBODY PERSISTENCE AT 2, 3, 4, 5 AND 6 YEARS AFTER A BOOSTER DOSE OF MENINGOCOCCAL SEROGROUP A, C, W-135, Y- TETANUS TOXOID CONJUGATE VACCINE (MENACWY-TT) OR MENINGITEC (REGISTERED) ADMINISTERED IN HEALTHY 5-YEAR-OLD CHILDREN IN STUDY MENACWY-TT-048 EXT: 039 Y2, 3, 4, 5 (112036), WHO WERE PRIMED WITH THE SAME VACCINE IN STUDY MENACWY-TT-039 (109670) AT 12 THROUGH 23 MONTHS OF AGE.
Conditions
Interventions
Blood Sampling
Locations
10
Finland
Espoo Vaccine Research Clinic
Espoo, Finland
Tampereen yliopisto/ Etela-Helsingin rokotetutkimusklinikka
Helsinki, Finland
Helsinki East Vaccine Research Clinic
Helsinki, Finland
Tampereen Yliopisto/ Jarvenpaan rokotetutkimusklinikka
Jarvenpaa, Finland
Tampereen yliopisto/ Oulun rokotetutkimusklinikka
Oulu, Finland
Tampereen yliopisto/ Porin rokotetutkimusklinikka
Pori, Finland
Start Date
July 1, 2013
Primary Completion Date
November 1, 2017
Completion Date
November 1, 2017
Last Updated
June 17, 2019
NCT04886154
NCT01939158
NCT01266993
NCT02451514
NCT02946385
NCT02639351
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions